Sign In
Buy MKGAF
$168.90
-0.220 (-0.130%)
At Close: Jul 31, 2026
Evinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical Development
04:00am, Wednesday, 29'th Jul 2026
BAAR, Switzerland--(BUSINESS WIRE)--Evinova, a global leader in AI-native clinical development technology, today announced a new multi-year strategic collaboration to accelerate global clinical develo
Merck KGaA (OTCMKTS:MKGAF) Shares Gap Up – Should You Buy?
02:02am, Sunday, 26'th Jul 2026
Merck KGaA (OTCMKTS:MKGAF - Get Free Report)'s share price gapped up before the market opened on Friday. The stock had previously closed at $154.0790, but opened at $163.5950. Merck KGaA shares last t
Merck KGaA (MKKGY) Moves to Strong Buy: Rationale Behind the Upgrade
01:01pm, Thursday, 23'rd Jul 2026
Merck KGaA (MKKGY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Merck KGaA (OTCMKTS:MKGAF) Shares Gap Up – Here’s Why
04:02am, Sunday, 19'th Jul 2026
Merck KGaA (OTCMKTS:MKGAF - Get Free Report) gapped up before the market opened on Friday. The stock had previously closed at $154.9360, but opened at $161.12. Merck KGaA shares last traded at $161.09
Merck KGaA (MKKGY) Soars 5.3%: Is Further Upside Left in the Stock?
10:01am, Friday, 26'th Jun 2026
Merck KGaA (MKKGY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Merck Germany Lands Bio-Techne In $11.3 Billion Cash Deal
09:34am, Thursday, 25'th Jun 2026
Merck KGaA (OTC:MKKGY) (OTC:MKGAF) on Thursday agreed to acquire Bio-Techne Corporation (NASDAQ:TECH) in an all-cash transaction valued at approximately $11.3 billion, as the German science and techno
Germany's Merck Is Buying Bio-Techne for $11.3 Billion
07:18am, Thursday, 25'th Jun 2026
Bio-Techne stock jumps, with Germany's Merck KGaA buying the company at a 24% premium.
Germany's Merck to buy Bio-Techne for $73 per share
06:09am, Thursday, 25'th Jun 2026
Merck KGaA has agreed to acquire biotech firm Bio-Techne Corp for $73 per share in cash, the German science and healthcare firm said in a statement on Thursday.
Germany's Merck to Buy Bio-Techne for $11 Billion
06:08am, Thursday, 25'th Jun 2026
Merck KGaA offered $73 a share in cash to buy Bio-Techne, representing a 24% premium to the U.S. lab-tools supplier's closing price Wednesday.
Should Value Investors Buy Merck KGaA (MKKGY) Stock?
10:40am, Monday, 18'th May 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Merck KGaA (MKKGY) Q1 2026 Earnings Call Transcript
10:50pm, Wednesday, 13'th May 2026
Merck KGaA (MKKGY) Q1 2026 Earnings Call Transcript
Merck KGaA Q1 Earnings Call Highlights
10:08am, Wednesday, 13'th May 2026
Merck KGaA ETR: MRK reported what executives described as a “solid start” to 2026, with organic growth in its Life Science and Electronics businesses offsetting a decline in Healthcare, and raised
Merck KGaA (MKKGY) Surpasses Q1 Earnings and Revenue Estimates
08:11am, Wednesday, 13'th May 2026
Merck KGaA (MKKGY) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.59 per share a year ago.
Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
08:05am, Thursday, 30'th Apr 2026
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT0
Merck KGaA: Small Breakout In 2026, Followed By Normalization
09:48pm, Sunday, 26'th Apr 2026
Merck KGaA is rated a 'Buy' with a revised price target of €127/share, reflecting strong fundamentals and resilient business segments. I expect 2026 to be a transition year with AEPS decline due to
